Testing immune responses to predict melanoma treatment outcomes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the immune response of patients with advanced melanoma undergoing combined immunotherapy with nivolumab and ipilimumab. It aims to identify predictive biomarkers, specifically levels of Th1, Th2, and Th17 cytokines, that correlate with treatment efficacy and tolerability. By analyzing cytokine production at the start and during treatment, the study seeks to establish a relationship between immune response and patient outcomes. The goal is to improve the management of immunotherapy by predicting which patients are likely to benefit from treatment.

Why it matters

Who can join: the full rules

Inclusion

* persone of major age,
* advanced melanoma confirmed,
* RECIST 1.1 disease,
* first line treatment

Exclusion Criteria:

* occular and mucosal melanoma,
* previous checkpoint inhibitor treatment,
* active brain metastasis,
* concomitant immunosuppressive treatment

Where it's running

• CHU de Nice - Hôpital de l'Archet
  Nice, Alpes-maritimes, France Recruiting
• CHU de Montpellier
  Montpellier, Occitanie, France Recruiting
• CHRU de Lille
  Lille, France Not yet recruiting

Study contacts

• Principal investigator: Montaudie Henri, PhD — CHU de Nice, Service de Dermatologie
• Study coordinator: Montaudie Henri, PhD
• Email: montaudie.h@chu-nice.fr
• Phone: 33492036083

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Assessing the safety and effectiveness of ENV-501 in patients with HER3-expressing solid tumors

  This study is testing a new treatment called ENV-501 to see if it is safe and effective for people with advanced solid tumors that express HER3, like melanoma, lung cancer, and breast cancer.

  Recruiting at 5 sites Phase 1/2 Hummingbird Bioscience · La Jolla, California and 6 other locations · NCT06956690

• Assessing a test to predict treatment response in advanced melanoma patients

  This study tests if the IOpener® melanoma test can help predict how well treatment will work for people with advanced melanoma who are starting their first-line therapy.

  Recruiting at 3 sites Pamgene International B.V. · Tübingen, Baden-Wurttemberg and 2 other locations · NCT06784778

• Monitoring the effects of encorafenib and binimetinib in melanoma treatment

  This study is testing how the levels of two melanoma drugs, encorafenib and binimetinib, affect side effects and treatment success in adults with a specific type of advanced melanoma.

  Recruiting Assistance Publique - Hôpitaux de Paris · Boulogne-Billancourt · NCT06774989

• Using Cyclophosphamide and Pembrolizumab for advanced melanoma treatment

  This study is testing if a combination of Cyclophosphamide and Pembrolizumab can help people with advanced melanoma who haven't responded to other treatments feel better and improve their health.

  Recruiting Phase 2 University of California, Irvine · Orange, California · NCT06771544

• Skipping full lymph node removal for stage III melanoma patients who show a strong response in the index node

  This trial will see if patients with resectable stage III melanoma who get neoadjuvant ipilimumab plus nivolumab and show a major pathological response in the index lymph node can safely avoid therapeutic lymph node dissection.

  Recruiting Erasmus Medical Center · Rotterdam, South Holland · NCT06754904

• Evaluating the DermaSensor device for detecting melanoma

  This study is testing a new device to see if it can accurately detect skin lesions that might be melanoma in people aged 40 and older.

  Recruiting at 2 sites DermaSensor, Inc. · New Smyrna Beach, Florida and 1 other locations · NCT06666790

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.